Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Krzysztof W. Selmaj"'
Autor:
Tomasz Siwek, Beata Zwiernik, Katarzyna Jezierska-Woźniak, Kamila Jezierska, Marcin P. Mycko, Krzysztof W. Selmaj
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
Background and objectivesX-linked adrenomyeloneuropathy (AMN) is an inherited neurodegenerative disorder associated with mutations in the ABCD1 gene and the accumulation of very long-chain fatty acids (VLFCAs) in plasma and tissues. Currently, there
Externí odkaz:
https://doaj.org/article/28e5e084c7b24247bd4a6fdba752becc
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Circular RNA (circRNA) molecules represent a novel and unique class of endogenous non-coding RNAs controlling the expression and function of microRNA (miRNA) and post-transcriptional regulation. Recent studies implicated circRNA in the pathomechanism
Externí odkaz:
https://doaj.org/article/211f0a8217c842d2aef1bba4905f1dc7
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Autor:
Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass, Aaron L. Boster, D. Alastair S. Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H. Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C. Chirieac, Krzysztof W. Selmaj
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous interferon beta-1a (SC IFNB-1
Externí odkaz:
https://doaj.org/article/0fa2ae77784345bda11b4afff0c00fe1
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 8, p 2823 (2020)
T helper cells type 17 (Th17) are orchestrators of autoimmune conditions, including multiple sclerosis (MS), but mechanisms of Th17 pathogenicity remain unknown. MicroRNAs (miRNA) are known to control T cells. To understand the function of miRNA in T
Externí odkaz:
https://doaj.org/article/c0eb1dbdbe814560b15b76d20b2058a6
Publikováno v:
Current Opinion in Neurology. 35:286-292
Autor:
Robert T. Naismith, Jeffrey A. Cohen, Amit Bar-Or, Giancarlo Comi, Krzysztof W. Selmaj, Hans-Peter Hartung, James K. Sheffield, Anthony Krakovich, Chun-Yen Cheng, Jennifer Reardon, Jon V. Riolo, Diego Silva, Bruce A. C. Cree
Publikováno v:
Tuesday, April 25.
Autor:
Colin M. Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F. Hunter, Krzysztof W. Selmaj, Hans-Peter Hartung, Eva K. Havrdova, Christopher C. LaGanke, Tjalf Ziemssen, Bart Van Wijmeersch, Sven G. Meuth, David H. Margolin, Elizabeth M. Poole, Darren P. Baker, Peter A. Senior
Publikováno v:
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 9:205521732211427
Background Alemtuzumab is an effective therapy for relapsing multiple sclerosis. Autoimmune thyroid events are a common adverse event. Objective Describe endocrine and multiple sclerosis outcomes over 6 years for alemtuzumab-treated relapsing multipl
Autor:
Marcin Mycko, Krzysztof W. Selmaj
Publikováno v:
Annals of Neurology. 45:546-547
Publikováno v:
Brain: A Journal of Neurology; May2003, Vol. 126 Issue 5, p1048-1057, 10p